Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
JUNS 
Jupiter Neurosciences, Inc. Common Stock (JUNS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: JUNS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 78.82% | Avg. Invested days 94 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.78M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 0.51 - 19.51 | Updated Date 10/17/2025 |
52 Weeks Range 0.51 - 19.51 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -175.6% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 28.65 | Enterprise Value 58227515 | Price to Sales(TTM) - |
Enterprise Value 58227515 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 34833083 | Shares Floating 16206440 |
Shares Outstanding 34833083 | Shares Floating 16206440 | ||
Percent Insiders 54.64 | Percent Institutions 0.23 |
Upturn AI SWOT
Jupiter Neurosciences, Inc. Common Stock
Company Overview
History and Background
Jupiter Neurosciences, Inc. is a biopharmaceutical company focused on the development of treatments for neurological and rare diseases. Founded in 2015, it is developing a next-generation therapeutic to treat neurological diseases.
Core Business Areas
- Drug Development: Researching and developing pharmaceutical products targeting neurological disorders.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The company has a typical corporate structure with a board of directors and various departments overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- JOTROL (JN-100): JN-100 is being investigated for the potential treatment of Mucopolysaccharidosis Type III (MPS III) and other neurological conditions. Market share data is currently unavailable as the product is in clinical development. Competitors depend on the indication and include other therapies in development for rare disease and those offering symptomatic relief.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. It is driven by innovation and the need for new treatments for unmet medical needs.
Positioning
Jupiter Neurosciences is a clinical-stage company seeking to develop novel treatments for neurological disorders. Its competitive advantage is its approach to treating neurological disorders with JOTROL.
Total Addressable Market (TAM)
The TAM for neurological disease treatments is very large. Jupiter Neurosciences aims to capture a portion of this market by targeting specific indications and improving patient outcomes.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Early stage of development
- Dependence on clinical trial success
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- SAN
- BIIB
- LLY
Competitive Landscape
Jupiter Neurosciences faces competition from established pharmaceutical companies with greater resources and experience. Its success depends on demonstrating the superior efficacy and safety of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: No historical revenue growth as the company is in the development stage.
Future Projections: Future growth is contingent on the successful development and commercialization of its drug candidates. Analyst estimates vary widely based on the potential market opportunity and the likelihood of regulatory approval.
Recent Initiatives: Focus on clinical trials of JOTROL (JN-100) and exploration of additional neurological indications.
Summary
Jupiter Neurosciences is a high-risk, high-reward biopharmaceutical company focused on developing treatments for neurological diseases. Its success hinges on the outcome of its clinical trials and its ability to secure funding. While it has a novel therapeutic approach, it faces significant competition and regulatory hurdles. Investors should be aware of the speculative nature of investing in early-stage biotechnology companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in biopharmaceutical companies is highly speculative and involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jupiter Neurosciences, Inc. Common Stock
Exchange NASDAQ | Headquaters Jupiter, FL, United States | ||
IPO Launch date 2024-12-03 | Co-Founder, CEO & Chairman of the Board Mr. Christer Rosen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://jupiterneurosciences.com |
Full time employees 4 | Website https://jupiterneurosciences.com | ||
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.